Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
Williams GS, Mistry B, Guillard S, Ulrichsen JC, Sandercock AM, Wang J, González-Muñoz A, Parmentier J, Black C, Soden J, Freeth J, Jovanović J, Leyland R, Al-Lamki RS, Leishman AJ, Rust SJ, Stewart R, Jermutus L, Bradley JR, Bedian V, Valge-Archer V, Minter R, Wilkinson RW.
Williams GS, et al. Among authors: jermutus l.
Oncotarget. 2016 Oct 18;7(42):68278-68291. doi: 10.18632/oncotarget.11943.
Oncotarget. 2016.
PMID: 27626702
Free PMC article.